How to Navigate Compassionate Use Programs in Rare Disease Regulation

Introduction: The Role of Compassionate Use in Rare Disease Access

For patients with rare and life-threatening diseases, access to investigational therapies before formal marketing authorization can be life-saving. Compassionate Use—also known as Expanded Access—provides a regulated pathway for patients who are not eligible for clinical trials to receive promising treatments still under investigation.

These programs are especially critical in rare disease landscapes, where standard treatment options are often nonexistent. Regulatory bodies like the U.S. FDA and the European Medicines Agency (EMA) have developed structured approaches to enable this access while maintaining safety and ethical standards.

Understanding the Regulatory Terminology

Compassionate Use varies in name and scope across jurisdictions. Below is a comparison of terms and frameworks:

Each system has slightly different eligibility requirements, documentation, and timelines, but the core principles of unmet need and ethical oversight are universal.

Types of Compassionate Use Access

Expanded access can take several forms depending on the scope and regulatory body:

• Single Patient IND: For individual cases, including emergencies (U.S. FDA)
• Intermediate-size Patient Population: For groups not eligible for a clinical trial
• Treatment IND: For broader access during the drug’s late-stage development
• Named Patient Program (EU): Physicians request unapproved drugs for specific patients
• Group Program: Coordinated use for defined patient categories (e.g., compassionate use for a genetic subtype)

Eligibility Criteria for Compassionate Use

Although terminology and scope vary, the typical eligibility requirements are:

• Patient has a serious or life-threatening condition
• No comparable or satisfactory alternative therapies
• Patient is not eligible for ongoing clinical trials
• Potential benefits outweigh the anticipated risks
• Access will not interfere with the drug’s development program

In all cases, regulatory agencies require submission of safety data, physician certifications, and IRB/ethics committee approvals before treatment begins.

Continue Reading: Application Process, Ethical Considerations, and Global Case Studies

Application Process for Compassionate Use Programs

The process for obtaining access to an investigational product under compassionate use involves multiple steps, which vary by jurisdiction but generally follow a consistent structure:

1. Physician Request: The treating physician initiates the request and confirms that the patient meets eligibility criteria.
2. Sponsor Consent: The drug sponsor must agree to provide the investigational product and often assists with regulatory documentation.
3. Ethics Committee/IRB Approval: Mandatory for protecting patient rights and ensuring ethical justification.
4. Regulatory Submission: A formal application is submitted to the competent authority (e.g., FDA, EMA, Health Canada).
5. Treatment Authorization: Once approved, treatment can begin under strict monitoring and reporting requirements.

In the U.S., the ClinicalTrials.gov platform also allows sponsors to register their expanded access programs to improve transparency.

Ethical and Legal Considerations

Providing investigational drugs outside clinical trials raises several ethical and regulatory questions. Common concerns include:

• Informed Consent: Patients must fully understand that the product is not yet approved, and its safety/efficacy is unproven.
• Equity and Fairness: Access should be based on medical need, not personal connections or geography.
• Impact on Clinical Trials: Widespread use of compassionate use could reduce enrollment in pivotal studies.
• Data Collection: Sponsors must ensure any data collected under compassionate use aligns with GCP and regulatory expectations.

To mitigate these concerns, some sponsors create internal review boards to assess compassionate use requests independently from clinical operations.

Data Reporting and Post-Treatment Obligations

Compassionate use programs require robust documentation and follow-up. Common post-treatment regulatory requirements include:

• Submission of safety reports, including SAEs and SUSARs
• Ongoing benefit-risk assessments and potential adjustments to access criteria
• Annual summaries of patient outcomes for regulatory review
• Final report outlining the scope and results of the access program

EMA expects these reports as part of the pharmacovigilance package during marketing authorization review. FDA may incorporate the findings into approval considerations if collected under proper protocol.

Case Study: Compassionate Use in Spinal Muscular Atrophy (SMA)

In 2017, prior to full approval of a gene therapy for SMA, a compassionate use program was initiated for children with advanced disease stages. The program was administered under an FDA expanded access protocol and EMA’s Named Patient Program. Key features included:

• Centralized eligibility screening to ensure fair allocation
• Strict follow-up requirements for adverse events
• Real-time safety data submission to regulators
• Post-treatment monitoring up to 24 months

The data helped strengthen the marketing application and reassured regulators about the product’s safety and usability outside controlled settings.

Global Challenges and Future Outlook

Despite the value of compassionate use, global implementation faces several challenges:

• Lack of harmonized regulations across countries
• High administrative burden on physicians and sponsors
• Limited awareness among patient communities
• Ethical dilemmas in prioritizing patients for access

Future regulatory reform may focus on creating global access frameworks, simplifying application procedures, and enabling responsible use of real-world data generated from compassionate use.

Conclusion: Balancing Access, Ethics, and Safety

Compassionate Use Programs offer a critical bridge between investigational development and real-world patient need. Especially in rare diseases, where patients face dire prognoses, these programs reflect a balance of innovation, access, and ethical responsibility.

To navigate compassionate use from a regulatory perspective, sponsors and physicians must understand regional frameworks, adhere to ethical standards, and maintain transparent documentation. In doing so, they contribute not just to individual patient care but also to regulatory trust and long-term therapy development.

Ethical and Regulatory Perspectives on Compassionate Use in Rare Disease Treatment

Understanding Compassionate Use and Expanded Access Programs

For patients with rare and life-threatening diseases, conventional treatment options are often limited or nonexistent. When clinical trial participation is not feasible due to geographic, medical, or eligibility limitations, compassionate use—or expanded access—offers a critical alternative pathway for accessing investigational therapies outside of clinical trials. These programs allow patients to receive potentially life-saving treatments before formal regulatory approval, under strict conditions and ethical oversight.

Expanded Access Programs (EAPs) are regulated by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), offering a structured mechanism for pre-approval treatment in exceptional circumstances. In rare disease communities, where the urgency of need is amplified by the lack of alternatives, EAPs are often the only hope for patients with deteriorating conditions.

Regulatory Frameworks Across Different Jurisdictions

The regulatory approach to compassionate use varies by region. Understanding these frameworks is crucial for sponsors and clinicians working in rare disease spaces.

• FDA (USA): Allows expanded access under 21 CFR 312 Subpart I. Individual, intermediate-size, and widespread EAPs are permitted. IRB approval and informed consent are required.
• EMA (EU): Each member state regulates access, though guidance exists under Article 83 of Regulation (EC) No 726/2004. Sponsors typically coordinate with national agencies like ANSM (France) or MHRA (UK).
• Japan: Provides an Early Access Program (EAP) to allow use of unapproved drugs after positive Phase II data.
• Australia: Offers the Special Access Scheme (SAS) through the Therapeutic Goods Administration (TGA).

For example, a biotech company providing a gene therapy for a rare metabolic disorder implemented a multi-country EAP following positive Phase II results, using local regulations to support early access in Canada, Brazil, and Italy.

Ethical Principles Underpinning Compassionate Use

Despite its noble intent, expanded access raises important ethical considerations, particularly regarding fairness, safety, and resource allocation. Core principles include:

• Equity: Access should not be limited to those with greater resources or advocacy.
• Transparency: Criteria for eligibility and prioritization must be clearly defined.
• Non-maleficence: Risks must be weighed against uncertain benefits.
• Informed consent: Patients must fully understand the experimental nature of the treatment.
• Scientific integrity: Access should not compromise ongoing clinical trials.

For instance, in one EAP for a rare pediatric neurodegenerative condition, the sponsor worked with bioethicists and advocacy groups to design an allocation process that included medical urgency, age limits, and geographic representation as key criteria.

Process for Implementing an Expanded Access Program

Setting up an EAP requires alignment between sponsors, investigators, regulators, and ethics committees. Typical steps include:

1. Determine eligibility: Only patients with serious or life-threatening conditions and no alternative treatment options qualify.
2. Submit documentation: An IND or protocol amendment must be submitted to FDA or relevant local authority.
3. Obtain IRB approval: Even for single-patient access, institutional oversight is necessary.
4. Informed consent: Must outline risks, benefits, and the unapproved status of the drug.
5. Drug supply coordination: Sponsors must ensure proper labeling, storage, and monitoring of the investigational product.
6. Adverse event reporting: Safety data must be collected and reported.

Expanded access is not a “back door” to treatment—it’s a carefully regulated bridge between clinical trials and formal market approval.

Challenges in Compassionate Use Implementation

Despite growing demand, EAPs are logistically and ethically complex. Common challenges include:

• Manufacturing capacity: Sponsors may have limited supplies of the investigational drug.
• Cost recovery: Many jurisdictions prohibit charging patients, posing financial strain on developers.
• Regulatory complexity: Each country has different timelines, documentation, and legal requirements.
• Patient selection: Ethical dilemmas arise when more patients seek access than the program can support.

In a real-world case, a biotech firm offering a rare enzyme replacement therapy faced overwhelming demand. A third-party ethics board was established to manage patient prioritization and ensure fair distribution based on clinical need.

The Role of Advocacy and Patient Engagement

Patient advocacy organizations play a crucial role in facilitating expanded access by:

• Educating families about compassionate use rights and options
• Connecting patients to enrolling EAPs or relevant sponsors
• Lobbying regulators for expedited access in ultra-rare indications
• Helping sponsors understand patient priorities and burdens

For example, advocacy groups like NORD and EURORDIS regularly partner with sponsors to build ethical frameworks for expanded access in ultra-rare diseases, ensuring programs are patient-centered and community-informed.

Right-to-Try Laws: Parallel or Problematic?

Some countries, like the U.S., have implemented “Right-to-Try” legislation allowing patients to directly request investigational drugs without FDA oversight. While this may sound empowering, ethical concerns remain:

• Bypasses standard safety reviews and IRB protections
• Lacks structured adverse event reporting
• Places pressure on sponsors to approve access requests without clear criteria

Many ethicists advocate for structured expanded access over Right-to-Try due to its stronger safeguards and data integrity. Still, both frameworks reflect the growing demand for earlier patient access to promising treatments.

Conclusion: Balancing Compassion and Caution

Compassionate use and expanded access are powerful tools for addressing the unmet needs of rare disease patients. When thoughtfully designed and ethically implemented, these programs offer hope to those who might otherwise face devastating outcomes. Yet they also demand careful balancing of urgency, fairness, and scientific rigor.

Sponsors and clinicians must collaborate with regulators, advocacy groups, and patient families to ensure that these programs remain ethically grounded, transparently administered, and focused on maximizing benefit while minimizing harm. As rare disease therapies continue to evolve, compassionate access will remain a critical complement to traditional clinical trial pathways.